Top

International Urology and Nephrology

Published in:

01-01-2020 | Rheumatoid Arthritis | Nephrology - Original Article

Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies

Authors: Sukit Raksasuk, Patompong Ungprasert

Published in: International Urology and Nephrology | Issue 1/2020

Abstract

Objectives

Patients with rheumatoid arthritis (RA) may have a higher risk of developing chronic kidney (CKD) compared with general population, but the data on this risk are still not well characterized. This systematic review and meta-analysis aimed to comprehensively investigate this association by reviewing all available studies.

Methods

A systematic review was performed using MEDLINE and EMBASE database from inception to July 2019 to identify all cohort studies that compared the risk of developing CKD after index date among patients with RA versus individuals without RA. Pooled risk ratio and 95% confidence interval (CI) were calculated using random-effect, generic inverse-variance method of DerSimonian and Laird.

Results

A total of four cohort studies (three retrospective cohort studies and four prospective cohort study) comprising of 1,627,833 participants met the inclusion criteria and were included in the meta-analysis. The overall quality of the included studies was good. The risk of incident CKD was significantly increased among patients with RA with the pooled risk ratio of 1.52 (95% CI 1.28–1.80). The statistical heterogeneity was high with an I² of 82%.

Conclusions

A significantly increased risk of incident CKD among patients with RA compared with individuals without RA was demonstrated in this study.

Available only for authorised users

Kohler BM, Gunther J, Kaudewitz D (2019) Current therapeutic options in treatment of rheumatoid arthritis. J Clin Med 8:E938. https://doi.org/10.3390/jcm8070938 CrossRefPubMed

Deane KD, Holers VM (2019) The natural history of rheumatoid arthritis. Clin Ther 41:1256–1269. https://doi.org/10.1016/j.clinthera.2019.04.028 CrossRefPubMed

Uhlig T, Moe RH, Kvien TK (2014) The burden of disease in rheumatoid arthritis. Pharmacoeconomics 32:841–851. https://doi.org/10.1007/s40273-014-0174-6 CrossRefPubMed

Malm K, Bergman S, Andersson M et al (2017) Quality of life in patients with established rheumatoid arthritis: a phenomenographic study. SAGE Open Med 5:2050312117713647. https://doi.org/10.1177/2050312117713647 CrossRefPubMedPubMedCentral

Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 35:10–14. https://doi.org/10.1016/j.jaut.2009.12.009 CrossRefPubMed

Crowson CS, Liao KP, Davis JM 3rd et al (2013) Rheumatoid arthritis and cardiovascular disease. Am Heart J 166:622–628. https://doi.org/10.1016/j.ahj.2013.07.010 CrossRefPubMedPubMedCentral

Cioffi G, Ognilbeni F, Dalbeni A et al (2018) High prevalence of occult heart disease in normotensive patients with rheumatoid arthritis. Clin Cardiol 41:736–743. https://doi.org/10.1002/clc.22926 CrossRefPubMedPubMedCentral

Ungprasert P, Srivali N, Kittanamongkolchai W (2017) Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis 20:434–441. https://doi.org/10.1111/1756-185X CrossRefPubMed

Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874. https://doi.org/10.1038/nature01323 CrossRefPubMed

10.

Rosenfeld ME (2013) Inflammation in atherosclerosis: direct versus indirect mechanisms. Curr Opin Pharmacol 13:154–160. https://doi.org/10.1016/j.coph.2013.01.003 CrossRefPubMedPubMedCentral

11.

Adcock IM, Mumby S (2017) Glucocorticoids. Handb Exp Pharmacol 237:171–196. https://doi.org/10.1007/164_2016_98 CrossRefPubMed

12.

Nakano M, Ueno M, Nishi S et al (1998) Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50:154–160PubMed

13.

Helin HJ, Korpela MM, Mustonen JT et al (1995) Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 38:242–247. https://doi.org/10.1002/art.1780380213 CrossRefPubMed

14.

Hippisley-Cox J, Coupland C (2010) Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of QKidney Scores. BMC Fam Pract 11:49. https://doi.org/10.1186/1471-2296-11-49 CrossRefPubMedPubMedCentral

15.

Hanaoka R, Kurasawa K, Tanaka A et al (2013) Active rheumatoid arthritis is an independent risk factor of chronic kidney disease. Arthritis Rheum 65(Suppl 10):S164–S165

16.

Hickson LJ, Crowson CS, Gabriel SE et al (2014) Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis 63:206–213. https://doi.org/10.1053/j.ajkd.2013.08.010 CrossRefPubMed

17.

Chiu HY, Huang HL, Li CH et al (2015) Increased risk of chronic kidney disease un rheumatoid arthritis associated with cardiovascular complications—a national population-based cohort study. PLoS One 10:e0136508. https://doi.org/10.1371/journal.pone.0136508 CrossRefPubMedPubMedCentral

18.

Sihvonen S, Korpela M, Mustonen J et al (2004) Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 96:107–114. https://doi.org/10.1159/000077372 CrossRef

19.

Al-Aly Z, Zeringue A, Fu J et al (2010) Rate of kidney function decline associates with mortality. J Am Soc Nephrol 21:1961–1969. https://doi.org/10.1681/ASN.2009121210 CrossRefPubMedPubMedCentral

20.

Swierkot J, Szechinski J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58:473–492PubMed

21.

Wells GA, Shea B, O’Connell D et al (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 10 July 2019

22.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trial 7:177–188CrossRef

23.

Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentral

24.

Ozyilmaz A, de Jong PE, Gansevoort RT (2012) Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage. Nephrol Dial Transplant 27:4046–4052. https://doi.org/10.1093/ndt/gfs438 CrossRefPubMed

25.

Yang X, Chang Y, Wei W (2016) Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediat Inflamm 2016:6813016. https://doi.org/10.1155/2016/6813016 CrossRef

26.

Ambrosino P, Lupoli R, Di Minno A et al (2015) Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost 113:916–930. https://doi.org/10.1160/TH14-11-0921 CrossRefPubMed

27.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyzes: the PRISMA statement. PLoS Med 2009:e1000097. https://doi.org/10.1371/journal.pmed1000097 CrossRef

Title: Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies
Authors: Sukit Raksasuk
Patompong Ungprasert
Publication date: 01-01-2020
Publisher: Springer Netherlands
Keywords: Rheumatoid Arthritis
Chronic Kidney Disease
Published in: International Urology and Nephrology / Issue 1/2020
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02346-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients

The epidemiology and role of surgery in the treatment of urethral clear cell carcinoma

HPV infection in urology practice

Quality of life and cognitive and functional performance of octogenarians and nonagenarians undergoing hemodialysis

Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria

Prostatic epithelial cells and their high expressions of CKIP-1 affect the TGF-β1 expression levels which might reduce the scar formation in remodeling stage at prostatic urethral wounds after wound repair

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials